Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 64264681

Next Previous
Drug Profile

JNJ 64264681

Alternative Names: JNJ-4681; JNJ-64264681

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • No development reported Cancer

Most Recent Events

  • 28 May 2025 Janssen Research & Development completes phase I clinical trials in Chronic lymphocytic leukaemia in US, Georgia, Moldova, Poland, Taiwan, Ukraine and the UK (PO) (NCT04210219)
  • 28 May 2025 Janssen Research & Development completes phase I clinical trials in Non-Hodgkin's lymphoma in US, Georgia, Moldova, Poland, Taiwan, Ukraine and the UK (PO) (NCT04210219)
  • 11 Apr 2025 Janssen Research & Development completes a Phase-I clinical trials in Chronic lymphocytic leukaemia (Combination therapy) in US, France, Australia, Belgium, Georgia, Israel, South Korea, Spain, Moldova, Netherlands, Poland and Ukraine (PO) (NCT04657224)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top